Go Pro
→ Should You Convert a Traditional IRA to a Roth After 60? (From SmartAsset) (Ad)tc pixel Free CHGCY Stock Alerts

Chugai Pharmaceutical (CHGCY) Stock Forecast & Price Target

Chugai Pharmaceutical logo
$21.05 +0.05 (+0.24%)
As of 09/25/2026 03:59 PM Eastern
Compare

Chugai Pharmaceutical - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Moderate Buy
Based on 5 Analyst Ratings
Sell
0
Hold
3
Buy
2

Based on 5 Wall Street analysts who have issued ratings for Chugai Pharmaceutical in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 5 analysts, 3 have given a hold rating, 1 has given a buy rating, and 1 has given a strong buy rating for CHGCY.

Consensus Price Target

N/A

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for CHGCY and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Chugai Pharmaceutical and its competitors.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CHGCY Analyst Ratings Over Time

TypeCurrent Forecast
9/26/25 to 9/26/26		1 Month Ago
8/27/25 to 8/27/26		3 Months Ago
6/28/25 to 6/28/26		1 Year Ago
9/26/24 to 9/26/25
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
2 Strong Buy rating(s)
 N/A
Buy
1 Buy rating(s)
1 Buy rating(s)
1 Buy rating(s)
 N/A
Hold
3 Hold rating(s)
2 Hold rating(s)
1 Hold rating(s)
 N/A
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
 N/A
Consensus Price TargetN/AN/AN/AN/A
Forecasted UpsideN/AN/AN/AN/A
Consensus RatingModerate BuyModerate BuyBuyN/A

CHGCY Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

CHGCY Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Chugai Pharmaceutical Stock vs. The Competition

TypeChugai PharmaceuticalHealthcare CompaniesBroader Market
Consensus Rating Score
2.60
2.31
2.53
Consensus RatingModerate BuyHoldModerate Buy
Predicted UpsideN/A763.55% Upside19.21% Upside
News Sentiment Rating
Negative News

See Recent CHGCY News
Positive News
Positive News
Export
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside		Details
9/1/2026
Nomura logo
Nomura
4 of 5 stars
 UpgradeHold
8/6/2026
UBS Group AG logo
UBS Group
4 of 5 stars
 DowngradeStrong-Buy ➝ Hold
6/15/2026
The Goldman Sachs Group, Inc. logo
The Goldman Sachs Group
3 of 5 stars
 UpgradeHold ➝ Buy
5/29/2026
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 UpgradeHold
2/25/2026
Smbc Nikko Sec. logo
Smbc Nikko Sec.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 UpgradeStrong-Buy

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 01:47 PM ET.


Should I Buy Chugai Pharmaceutical Stock? CHGCY Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, September 22, 2026. Please send any questions or comments about these Chugai Pharmaceutical pros and cons to contact@marketbeat.com.

Chugai Pharmaceutical
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Chugai Pharmaceutical Co., Ltd.:

  • The stock is currently trading at $21.66, which is near its 52-week low of $20.00, potentially offering a value entry point for investors looking to capitalize on a potential rebound from recent price declines.
  • Chugai Pharmaceutical Co., Ltd. maintains a strong financial profile with a net margin of 35.09% and a return on equity of 23.76% in its most recent quarter, indicating efficient profit generation and effective use of shareholder capital.
  • The company has a low beta of 0.59, suggesting that its stock price is less volatile than the overall market, which may appeal to risk-averse investors seeking stability in their portfolio.
  • Chugai Pharmaceutical Co., Ltd. offers a dividend yield of 1.14%, providing a modest income stream for investors while they hold the stock.
  • Analysts have recently issued a consensus rating of "Moderate Buy," with Goldman Sachs upgrading the stock to a "buy" rating in June 2026, reflecting positive institutional sentiment toward the company's outlook.

Chugai Pharmaceutical
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Chugai Pharmaceutical Co., Ltd. for these reasons:

  • Short interest in the stock increased by 90.3% in August 2026, rising to 27,111 shares, which may indicate growing bearish sentiment among traders who expect the stock price to decline.
  • The company's revenue of $2.14 billion in the most recent quarter missed analyst estimates of $2.38 billion, suggesting potential challenges in meeting market expectations for top-line growth.
  • Chugai Pharmaceutical Co., Ltd. has a price-to-earnings ratio of 23.54, which is relatively high and may limit upside potential if earnings growth does not accelerate to justify the valuation.
  • The stock has underperformed its 200-day simple moving average of $24.67, indicating a longer-term downtrend that could continue if broader market conditions remain unfavorable.
  • UBS Group downgraded the stock from "strong-buy" to "hold" in August 2026, reflecting a more cautious outlook from a major financial institution regarding the company's near-term prospects.

CHGCY Forecast - Frequently Asked Questions

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chugai Pharmaceutical in the last year. There are currently 3 hold ratings, 1 buy rating and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" CHGCY shares.

According to analysts, Chugai Pharmaceutical's stock has a predicted downside of -100.00% based on their 12-month stock forecasts.

Over the previous 90 days, Chugai Pharmaceutical's stock had 1 upgrade and 1 downgrade by analysts.

Chugai Pharmaceutical has been rated by research analysts at Nomura, and UBS Group in the past 90 days.

Analysts like Chugai Pharmaceutical more than other "healthcare" companies. The consensus rating for Chugai Pharmaceutical is Moderate Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how CHGCY compares to other companies.

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Chugai Pharmaceutical Recommendations


MarketBeat monitors more than a dozen sources for Chugai Pharmaceutical analyst ratings, with the most recent rating issued on 9/1/2026.
From Our Partners
A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...
Porter & Company | Sponsoredtc pixel
I'm giving you a space stock today. Free.
On December 8th, $600 billion in frozen SpaceX stock comes loose. Dylan Jovine says one simple purchase in any...
Behind the Markets | Sponsoredtc pixel
The end of AI data centers coming?
Marc Chaikin's Power Gauge system flagged Micron before it soared 970 percent, Celestica before a 6,600 percen...
Chaikin Analytics | Sponsoredtc pixel
Major Buy Alert Issued for September 30th
Keith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...
TradeSmith | Sponsoredtc pixel
"How Much Can I Actually Spend Each Year With $2.5M Saved?"
Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you...
SmartAsset | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Did you forget to grab this?
Most beginners stay stuck on the sidelines for years because no one shows them the simple steps between being ...
Profits Run | Sponsoredtc pixel
Why This Small AI Company Holds 150 Patents
Jeff Brown, the tech investor who identified Nvidia in 2016 before its 37,000% run, has flagged a new AI compa...
Brownstone Research | Sponsoredtc pixel